Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

That means Wojcicki’s nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s ...

Anne Wojcicki regains control of 23andMe, the company she co-founded and led as CEO, through her nonprofit TTAM with a $305 million bid at a bankruptcy auction.

TTAM will acquire substantially all of 23andMe’s assets for $305 million, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health.

The agreement with TTAM is the result of a final round of bidding that occurred earlier today between TTAM and Regeneron Pharmaceuticals, Inc. (“Regeneron”) (NASDAQ: REGN). The final round of ...

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it ...

Previous reports (including ours) said that a company named Regeneron was supposed to be the buyer, but that deal ended up ...

Anne Wojcicki’s bid to buy 23andMe, the genetic testing company she co-founded nearly 20 years ago, has received the court’s ...